MITO23

Randomized phase III  trial on  Trabectedin (ET 743) vs clinician’s choice chemotherapy   in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or  BRCAness phenotype patients 

Contact Person
Status
Completed
Disease Site
Ovarian
Lead Cooperative Group
Participating Groups
MaNGO
GCIG Number